Gilead Sciences’ Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a highly effective hepatitis C virus (HCV) treatment option for those whose previous direct-acting antiviral (DAA) regimen failed and who have evidence of resistance to certain hep C drug classes, MD Magazine reports.
Publishing their findings in the Journal of Hepatology, researchers conducted a study with 248 people whose hep C had not been cured by a prior DAA treatment for HCV and who had experience taking a medication in the NS5A inhibitor class.
Before 12 weeks of Vosevi treatment, 82.7 percent of the participants had either NS5A inhibitor– or NS3 inhibitor–related resistance-associated substitutions (RASs), which are mutations in hep C linked to drug resistance. A total of 79 percent had RASs to NS5A inhibitors.
Ninety-seven percent of the participants achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). There was no association between the initial presence of RASs and the chance of achieving a cure.
Of the seven participants who experienced viral relapse, only one had developed drug resistance prompted by taking Vosevi.
To read the MD Magazine article, click here.
To read the study abstract, click here.